- Category: HCV Disease Progression
- Published on Tuesday, 28 July 2015 00:00
- Written by Liz Highleyman
HIV/HCV coinfected people with cirrhosis who achieve sustained virological response (SVR) and experience an improvement in liver fibrosis are less likely to develop liver disease complications or die from liver-related causes -- and in some cases fibrosis regression is beneficial even in the absence of a cure -- according to a presentation at the 8th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention last week in Vancouver. A related study looked at predictors of liver fibrosis progression in HIV/HCV coinfected people, finding that use of certain NRTI "backbone"' antiretroviral drugs and HIV protease inhibitors may increase the risk.